{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:31:23Z","timestamp":1788877883232,"version":"build-2803163510"},"reference-count":50,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE:<\/jats:title><jats:p>To assess the safety of currently licensed diphtheria-tetanus-acellular pertussis (DTaP) vaccines in the United States by using data from the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>We searched VAERS for US reports of DTaP vaccinations occurring from January 1, 1991, through December 31, 2016, and received by March 17, 2017. We reviewed available medical records for all death reports and a random sample of reports classified as nondeath serious. We used Empirical Bayesian data mining to identify adverse events that were disproportionally reported after DTaP vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>VAERS received 50\u2009157 reports after DTaP vaccination; 43\u2009984 (87.7%) of them reported concomitant administration of other vaccines, and 5627 (11.2%) were serious. Median age at vaccination was 19 months (interquartile range 35 months). The most frequently reported events were injection site erythema (12\u2009695; 25.3%), pyrexia (9913; 19.8%), injection site swelling (7542; 15.0%), erythema (5599; 11.2%), and injection site warmth (4793; 9.6%). For 3 of the DTaP vaccines, we identified elevated values for vaccination errors using Empirical Bayesian data mining.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>No new or unexpected adverse events were detected. The observed disproportionate reporting for some nonserious vaccination errors calls for better education of vaccine providers on the specific indications for each of the DTaP vaccines.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.2017-4171","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T07:20:07Z","timestamp":1528096807000},"source":"Crossref","is-referenced-by-count":16,"title":["Safety Surveillance of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccines"],"prefix":"10.1542","volume":"142","author":[{"given":"Pedro L.","family":"Moro","sequence":"first","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Perez-Vilar","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Lewis","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe","family":"Bryant-Genevier","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Epidemiology Intelligence Service, Meningitis and Vaccine Preventable Diseases Branch, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia;"},{"name":"Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cano","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2018,7,1]]},"reference":[{"key":"2021121015163981900_B1","first-page":"1","article-title":"Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP).","volume":"40","year":"1991","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"2021121015163981900_B2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1542\/peds.68.5.650","article-title":"Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children.","volume":"68","author":"Cody","year":"1981","journal-title":"Pediatrics"},{"issue":"3","key":"2021121015163981900_B3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1542\/peds.85.3.294","article-title":"Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy.","volume":"85","author":"Long","year":"1990","journal-title":"Pediatrics"},{"key":"2021121015163981900_B4","first-page":"1","article-title":"Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Morb Mortal Wkly Rep. 1997;46(30):706].","volume":"46","year":"1997","journal-title":"MMWR Recomm Rep"},{"key":"2021121015163981900_B5","unstructured":"US Food and Drug Administration. Daptacel vaccine insert. Available at: www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm101572.htm. Accessed March 27, 2018"},{"key":"2021121015163981900_B6","unstructured":"US Food and Drug Administration. Infanrix vaccine insert. Available at: www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm101568.htm. Accessed March 27, 2018"},{"key":"2021121015163981900_B7","unstructured":"US Food and Drug Administration. Pediarix vaccine insert. Available at: www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm146759.htm. Accessed March 27, 2018"},{"key":"2021121015163981900_B8","unstructured":"US Food and Drug Administration. Pentacel vaccine insert. Available at: www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm172502.htm. Accessed March 27, 2018"},{"key":"2021121015163981900_B9","unstructured":"US Food and Drug Administration. Kinrix vaccine insert. Available at: www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm172495.htm. Accessed March 27, 2018"},{"key":"2021121015163981900_B10","unstructured":"US Food and Drug Administration. Quadracel vaccine insert. Available at: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM439903.pdf. Accessed March 27, 2018"},{"issue":"8","key":"2021121015163981900_B11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/00006454-200208000-00016","article-title":"Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids.","volume":"21","author":"Jackson","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2021121015163981900_B12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1542\/peds.2009-1496","article-title":"Lack of association between acellular pertussis vaccine and seizures in early childhood.","volume":"126","author":"Huang","year":"2010","journal-title":"Pediatrics"},{"issue":"3","key":"2021121015163981900_B13","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-1886","article-title":"Injection site and risk of medically attended local reactions to acellular pertussis vaccine.","volume":"127","author":"Jackson","year":"2011","journal-title":"Pediatrics"},{"issue":"2","key":"2021121015163981900_B14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1542\/peds.2012-2617","article-title":"Vaccination site and risk of local reactions in children 1 through 6 years of age.","volume":"131","author":"Jackson","year":"2013","journal-title":"Pediatrics"},{"issue":"44","key":"2021121015163981900_B15","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1016\/j.vaccine.2010.08.062","article-title":"Post-licensure comparison of the safety profile of diphtheria\/tetanus\/whole cell pertussis\/haemophilus influenza type b vaccine and a 5-in-1 diphtheria\/tetanus\/acellular pertussis\/haemophilus influenza type b\/polio vaccine in the United Kingdom.","volume":"28","author":"Andrews","year":"2010","journal-title":"Vaccine"},{"issue":"8","key":"2021121015163981900_B16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jama.2012.165","article-title":"Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B.","volume":"307","author":"Sun","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"2021121015163981900_B17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/aje\/kws317","article-title":"Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study.","volume":"177","author":"Nelson","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"25","key":"2021121015163981900_B18","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.vaccine.2014.03.063","article-title":"Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.","volume":"32","author":"Daley","year":"2014","journal-title":"Vaccine"},{"issue":"35","key":"2021121015163981900_B19","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1016\/j.vaccine.2016.06.062","article-title":"Safety of DTaP-IPV\/Hib vaccine administered routinely to infants and toddlers.","volume":"34","author":"Hansen","year":"2016","journal-title":"Vaccine"},{"key":"2021121015163981900_B20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.pediatrneurol.2017.08.005","article-title":"Febrile seizure risk after vaccination in children one to five months of age.","volume":"76","author":"Duffy","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"6","key":"2021121015163981900_B21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.inf.0000130075.56368.02","article-title":"Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993-2002.","volume":"23","author":"Moore","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"2021121015163981900_B22","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-1977","article-title":"A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.","volume":"122","author":"Zangwill","year":"2008","journal-title":"Pediatrics"},{"issue":"5","key":"2021121015163981900_B23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archpedi.1996.02170300011001","article-title":"The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment.","volume":"150","author":"Rosenthal","year":"1996","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"4","key":"2021121015163981900_B24","doi-asserted-by":"crossref","DOI":"10.1542\/peds.106.4.e51","article-title":"Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years\u2019 data from the Vaccine Adverse Event Reporting System (VAERS).","volume":"106","author":"Braun","year":"2000","journal-title":"Pediatrics"},{"issue":"36","key":"2021121015163981900_B25","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"2021121015163981900_B26","unstructured":"Medical dictionary for regulatory activities. Available at: www.meddra.org. Accessed March 27, 2018"},{"key":"2021121015163981900_B27","unstructured":"International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. MedDRA. Available at: www.ich.org\/products\/meddra.html. Accessed March 27, 2018"},{"key":"2021121015163981900_B28","first-page":"52252","article-title":"21 CFR Part 600.80. Postmarketing reporting of adverse experiences.","volume":"62","author":"Food and Drug Administration","year":"1997","journal-title":"Fed Regist"},{"issue":"31","key":"2021121015163981900_B29","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.","volume":"25","author":"R\u00fcggeberg","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"2021121015163981900_B30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system.","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"issue":"6","key":"2021121015163981900_B31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database.","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"2","key":"2021121015163981900_B32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1586\/14760584.1.2.161","article-title":"Methods of ensuring vaccine safety.","volume":"1","author":"Ball","year":"2002","journal-title":"Expert Rev Vaccines"},{"key":"2021121015163981900_B33","unstructured":"Centers for Disease Control and Prevention. Recommended immunization schedule for children and adolescents aged 18 years or younger; United States, 2018. Available at: https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/child-adolescent.html. Accessed March 27, 2018"},{"issue":"11","key":"2021121015163981900_B34","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.vaccine.2011.12.042","article-title":"Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the Vaccine Adverse Event Reporting System.","volume":"30","author":"Leroy","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"2021121015163981900_B35","first-page":"1","article-title":"Deaths: final data for 2014.","volume":"65","author":"Kochanek","year":"2016","journal-title":"Natl Vital Stat Rep"},{"issue":"1","key":"2021121015163981900_B36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.amepre.2013.02.020","article-title":"Mortality rates and cause-of-death patterns in a vaccinated population.","volume":"45","author":"McCarthy","year":"2013","journal-title":"Am J Prev Med"},{"issue":"1","key":"2021121015163981900_B37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pds.4141","article-title":"Vaccination and unexplained sudden death risk in Taiwanese infants.","volume":"26","author":"Huang","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021121015163981900_B38","unstructured":"Centers for Disease Control and Prevention. Sudden unexpected infant death and sudden infant death syndrome. Available at: www.cdc.gov\/sids\/. Accessed June 9, 2017"},{"issue":"31","key":"2021121015163981900_B39","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1016\/j.vaccine.2007.02.068","article-title":"Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life: case definition and guidelines for collection, analysis, and presentation of immunization safety data.","volume":"25","author":"Jorch","year":"2007","journal-title":"Vaccine"},{"key":"2021121015163981900_B40","volume-title":"Immunization Safety Review: Vaccinations and Sudden Unexpected Death in Infancy","author":"Institute of Medicine","year":"2003"},{"issue":"26","key":"2021121015163981900_B41","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1016\/j.vaccine.2007.02.077","article-title":"Do immunisations reduce the risk for SIDS? A meta-analysis.","volume":"25","author":"Vennemann","year":"2007","journal-title":"Vaccine"},{"issue":"2","key":"2021121015163981900_B42","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.vaccine.2006.07.027","article-title":"Sudden infant death syndrome: no increased risk after immunisation.","volume":"25","author":"Vennemann","year":"2007","journal-title":"Vaccine"},{"issue":"6","key":"2021121015163981900_B43","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2004-2185","article-title":"Probability of coincident vaccination in the 24 or 48 hours preceding sudden infant death syndrome death in Australia.","volume":"115","author":"Brotherton","year":"2005","journal-title":"Pediatrics"},{"issue":"9","key":"2021121015163981900_B44","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1097\/INF.0000000000001620","article-title":"Elevated immune response among children 4 years of age with pronounced local adverse events after the fifth diphtheria, tetanus, acellular pertussis vaccination.","volume":"36","author":"van der Lee","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"2021121015163981900_B45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1311738","article-title":"Risk of intussusception after monovalent rotavirus vaccination.","volume":"370","author":"Weintraub","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2021121015163981900_B46","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/INF.0b013e3181a9cc2a","article-title":"Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens.","volume":"28","author":"Scheifele","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"2021121015163981900_B47","unstructured":"Merck & Company. Rotateq vaccine insert. Available at: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/r\/rotateq\/rotateq_pi.pdf. Accessed March 27, 2018"},{"key":"2021121015163981900_B48","unstructured":"GlaxoSmithKline. Rotarix vaccine insert. Available at: https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Rotarix\/pdf\/ROTARIX-PI-PIL.PDF. Accessed March 27, 2018"},{"issue":"6","key":"2021121015163981900_B49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1303164","article-title":"Intussusception risk after rotavirus vaccination in U.S. infants.","volume":"370","author":"Yih","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2021121015163981900_B50","doi-asserted-by":"crossref","first-page":"e20160590","DOI":"10.1542\/peds.2016-0590","article-title":"Brief resolved unexplained events (formerly apparent life-threatening events) and evaluation of lower-risk infants.","volume":"137","author":"Tieder","year":"2016","journal-title":"Pediatrics"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2017-4171\/1065456\/peds_20174171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2017-4171\/1065456\/peds_20174171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T07:35:07Z","timestamp":1720337707000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/142\/1\/e20174171\/37518\/Safety-Surveillance-of-Diphtheria-and-Tetanus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,7,1]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2017-4171","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,1]]},"article-number":"e20174171"}}